Gene of the month: KRAS

Journal of Clinical Pathology

Volumn 66, Issue 7, 2013, Pages 548-550

  Chetty, Runjan ^a   Govender, Dhirendra ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN;

BILIARY TRACT CANCER; COLORECTAL CANCER; ENDOMETRIUM CANCER; GENE MUTATION; HUMAN; LIVER CANCER; LUNG CANCER; NEOPLASM; ONCOGENE K RAS; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; THYROID CANCER; TUMOR GENE; UTERUS CANCER;

CANCER; GENETICS; MOLECULAR PATHOLOGY;

CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84879411325     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2013-201663     Document Type: Review

References (24)

1. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827.
2. Ellis C, Clark G. The importance of being K-Ras. Cell Signal 2000;12:425-34.
3. Kato K, Cox A, Hisaka M, et al. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992;89:6403-7.
4. Magee A, Newman C, Giannakouros T, et al. Lipid modifications and function of the ras superfamily of proteins. Biochem Soc Trans 1992;20:497-9.
5. Quilliam L, Khosravi-Far R, Huff S, et al. Guanine nucleotide exchange factors: activators of the Ras superfamily of proteins. Bioessays 1995;17:395-404.
6. Bollag G, McCormick F. GTPase activating proteins. Semin Cancer Biol 1992;3:199-208.
7. Rozakis-Adcock M, Fernley R, Wade J, et al. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 1993;363:83-5. (Pubitemid 23144967)
8. Satoh T, Endo M, Nakafuku M, et al. Platelet-derived growth factor stimulates formation of active p21ras.GTP complex in Swiss mouse 3T3 cells. Proc Natl Acad Sci USA 1990;87:5993-7.
9. Wittinghofer A, Nassar N. How Ras-related proteins talk to their effectors. Trends Biochem Sci 1996;21:488-91. (Pubitemid 27018818)
10. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev 2003;3:7-13.
11. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem 2005;386:193-205. (Pubitemid 40485425)
12. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9:59-71.
13. Schlesinger T, Fanger G, Yujiri T, et al. The TAO of MEKK. Front Biosci 1998;3:D1181-D6.
14. Eberhard D, Johnson B, Amler L, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
15. Garcia-Rostan G, Zhao H, Camp R, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2005;21:3226-35.
16. Lee J, Jang K, Ki C, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007;109:1561-9. (Pubitemid 46595692)
17. Wang H, Lopategui J, Amin M, et al. KRAS mutation testing in human cancers: The Pathologist's role in the era of personalized medicine. Adv Anat Pathol 2010;17:23-32.
18. Hirsch F, Varella-Garcia M, Bunn PJ, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-807. (Pubitemid 46606235)
19. Gandhi J, Zhang J, Xie Y, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS 2009;4:e4576, 1-11.
20. Sharma S, Bell D, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
21. Riely G, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009;6:201-5.
22. Forrester K, Almoguera C, Han K. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987;327:298-303. (Pubitemid 17075080)
23. Vogelstein B, Fearon E, Hamilton S, et al. Genetic alterations during colorectal-tumor development. New Engl J Med 1988;319:525-32.
24. Morris J, Wang S, Hebrok M. KRAS, Hedghog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010;10:683-95.